E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Cystic fibrosis - a genetic disorder that results in thicker than usual bodily secretions, particularly affecting the lungs making them prone to infections and resulting in progressive lung disease. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10011762 |
E.1.2 | Term | Cystic fibrosis |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Is using Cayston plus one standard intravenous antibiotic as effective as two standard intravenous antibiotics in the treatment of an acute chest infections in people with cystic fibrosis? |
|
E.2.2 | Secondary objectives of the trial |
What changes occur in the bacterial community in the lung during treatment with Cayston plus an intravenous antibiotic and how do they compare to the changes seen when treatment is two intravenous antibiotics? |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Confirmed diagnosis of CF
Patients aged 18 - 65 years of age who have given informed consent
FEV1 >25% or <75% predicted (in keeping with Cayston® prescribing license)
Admitted to the Liverpool Heart and Chest Hospital with an exacerbation of CF pulmonary disease (as per modified Fuchs criteria)
Presence of Psa in lower respiratory tract cultures in the 6 months prior to screening
|
|
E.4 | Principal exclusion criteria |
Documented allergy to beta-lactam antibiotics or IV Colistin
Growth of Burkholderia Cepacia Complex (BCC) within 2 years
Pregnancy
Previous organ transplant
Receiving other clinical trial medication
Already prescribed regular Cayston®
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Average actual change from Day 0 (start of exacerbation) in forced expiratory volume in 1 second (FEV1) % predicted |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At 7 days, the end of each arm of study (day 14) and at 14 days post treatment (day 28) |
|
E.5.2 | Secondary end point(s) |
Time to first protocol-defined pulmonary exacerbation (or end point of 12 months if no subsequent exacerbation)
Rate of hospitalizations for a respiratory event (12 months)
Average change from baseline in the Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Symptom Scale (RSS) score at the end of each arm of study (Day 14)
Psa sputum counts, total bacterial load and 16S microbiome (From sputum taken at Day 0 and Day 14 in each arm of the study)
Prevalence of resistance to antibiotics and changes in antimicrobial resistance ( From sputum taken at Day and Day 14 in each arm of the study)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Whichever comes first from the following two option:
1/ 12 months after the last patient completes their second treatment arm.
2/ When all 16 patients have subsequently exacerbated and received IV antibiotics following their discharge after the second treatment arm. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 1 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 1 |